Oral Sleep Apnea Market - Growth, Trends, And Forecasts (2023 - 2028)

The oral sleep apnea market is expected to register a CAGR of 14.1% over the forecast period.

Initially, the COVID-19 pandemic substantially impacted the oral sleep apnea market. With the outbreak of COVID-19, the oral sleep apnea market experienced a hike in growth. It was primarily due to the elevated risk of respiratory failure in the COVID-19-infected patients. For the management of respiratory issues, oral sleep devices, such as mandibular advancement devices, were utilized to provide respiratory support to COVID-19 patients. The American Academy of Dental Sleep Medicine recommended using oral sleep appliances as the first-line therapy for sleep apnea in patients amid the pandemic. According to the American Academy of Sleep Medicine, oral sleep apnea devices work as an alternative therapy to invasive and infection-prone positive airway pressure (PAP) devices.

The massive spread of COVID-19 and the imposition of lockdown made it challenging for patients to visit their physicians, hospitals, or sleep clinics. However, telemedicine helped with the deeper penetration of oral sleep apnea therapies during COVID-19. Clinicians quickly adapted to telemedicine for their clinical practices, which helped them consult with several patients effectively. In a study published in Sleep Medicine 2022, over 10,171 sleep apnea patients were tele-consulted by the BlueSleep Center in March 2020 during the pandemic.

As per the analysis, the demand for oral sleep apnea therapies is expected to grow at a stable pace in the post-pandemic era. Several market participants have stated that sales of oral sleep devices have increased since the COVID-19 pandemic. For instance, in December 2021, SomnoMed stated that its revenue increased by 10% in the first half of the financial year 2022. It forecasted an estimated growth rate of 15% in the financial year 2022. Furthermore, Oventus Medical reported that the sales of oral sleep appliances had more than doubled between 2020 and 2021. Thus, with such an increase in the sales of devices as well as drugs, the market is expected to grow further at a stable pace.

Further, the rising prevalence of sleep apnea and an upsurge in the geriatric population, growing incidences of the underlying conditions associated with sleep apnea, and upcoming technological advancements in devices are likely to boost the market's growth over the coming years.

According to a study published in the Journal of the American Thoracic Society in 2022, obstructive sleep apnea (OSA) has a global prevalence of over 22.6%. Moreover, the enlarging geriatric population has a major impact on the demand for oral sleep apnea drugs and devices, as aged individuals have a high risk of developing this condition. For instance, according to a study published in the National Library of Medicine, in June 2022, nearly 1 billion people worldwide suffer from obstructive sleep apnea (OSA), with 425 million adults aged 30-69 having moderate-to-severe OSA. The study further states that when people reach 50 years or older, the prevalence increases with age, and the condition affects just as many women as men worldwide. Furthermore, the WHO predicts that by 2030, one out of every six people will be 60 years of age or older. Thus, a growing aging population more vulnerable to this condition will likely augment the demand for oral sleep apnea devices and drugs, propelling the market's growth.

In addition, the Sleep Health Organization in June 2022 stated that the medical comorbidity of obesity increases the risk of developing sleep apnea. The high body mass index causes difficulty breathing by obstructing the airway, reducing lung capacity, and causing throat collapse during sleep.

Additionally, several market players have received regulatory approvals and launched advanced oral sleep apnea products, which will propel the market's growth. For instance, in October 2022, Airway Management launched its customizable oral sleep appliance, flexTAP, dedicated to treating patients with snoring conditions and mild to moderate obstructive sleep apnea. The device combines patented Vertex Technology with the flexTAP Mouth Shield comfort accessory, which aids in nasal breathing and optimizes under or over-secretion of saliva. In February 2021, Oventus Medical launched its oral sleep appliance, O2Vent Optima, under its direct-to-consumer model and virtual lab. The company offers telehealth services associated with the oral sleep apnea device.

Therefore, owing to the aforementioned factors, it is anticipated that the studied market will witness growth over the analysis period. However, the high cost of oral sleep appliances and stringent regulatory policies will likely impede the market growth.

Oral Sleep Apnea Market Trends

Mandibular Advancement Devices Segment Expected to Witness Significant Growth

Mandibular advancement devices (MAD) are oral sleep apnea devices that adjust the jaw to expand the airways and assist in breathing during sleep. These devices are a non-invasive alternative to PAP devices and effectively treat mild to moderate sleep apnea. They are the primary treatment for sleep apnea, with mild to moderate severity in patients who feel uneasy with PAP devices. MAD devices offer the flexibility of being custom-made and offer desirable management of the problem. Several research publications have indicated the effectiveness of MADs in managing sleep apnea over the long term. For instance, a study published in the Journal of Craniomandibular & Sleep Practice in 2022 underlined the efficacy of MADs for managing mild to severe sleep apnea. These devices have shown positive results in reducing the apnea-hypopnea index (AHI) and sleep apnea-related symptoms, such as snoring, excessive daytime exhaustion, and unrefreshing sleep.

In addition, some key developments in mandibular advancement devices have further bolstered the market's growth. For instance, in July 2022, Glidewell launched its mandibular advancement device, the Silent Nite Sleep Appliance with Glidewell Hinge. The device is an extension of the Silent Nite brand, which dentists use to treat snoring and obstructive sleep apnea. Further, in September 2021, Vivos Therapeutics, Inc. received the USFDA's 510(k) market clearance for its mmRNA (modified mandibular repositioning nighttime appliance) oral appliance.

Therefore, owing to the abovementioned factors, such as efficacy, product launches, and regulatory approvals, the mandibular advancement devices segment is expected to witness significant growth over the forecast period.

North America Expected to Dominate the Oral Sleep Apnea Market

North America is expected to dominate the oral sleep apnea market owing to crucial factors, such as the high prevalence of sleep apnea, the vast geriatric population, and the advanced healthcare infrastructure. The presence of key manufacturers in the United States, as well as the increasing prevalence of the condition, are two of the primary reasons for market expansion. According to the AHA 2021, over 17% of middle-aged females and 34% of middle-aged men met the diagnostic criteria for obstructive sleep apnea in the United States. Furthermore, the high burden of obesity is expected to positively impact the market's growth. For instance, according to the Sleep Apnea Organization, in 2021, more than 30 million Americans suffered from sleep apnea, and 80% of moderate-to-severe sleep apnea cases were undiagnosed. The condition affects more than 20% of obese people every year.

Moreover, strategic developments by the leading players are one of the major factors driving the growth of the oral sleep apnea market. For instance, in May 2022, ProSomnus Holdings Inc. and Lakeshore Acquisition merged under the definitive business combination agreement to become ProSomnus, Inc. The deal is expected to accelerate the development and commercialization of ProSomnus' oral appliance therapy devices.

In October 2022, Panthera Dental signed an exclusive distribution agreement with MK1 Dental-Attachment GmbH to expand the oral sleep apnea and dental products offering in the United States and Canada. In May 2022, Panthera Dental, in collaboration with Medit Corp., announced the creation of a completely digital workflow to provide world-class custom-made snoring and obstructive sleep apnea management through an integrated digital workflow. Further, these continuous developments in the region are anticipated to drive the growth of the market.

Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North American region.

Oral Sleep Apnea Market Competitor Analysis

The oral sleep apnea market is moderately consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of some international and local companies that hold market shares and are well known, including SomnoMed, Whole You, Panthera Dental, ProSomnus Sleep Technologies, Oventus Medical, ResMed, DynaFlex, Airway Management, OravanOSA, Myerson LLC, MPowrx Health & Wellness, Vivos Therapeutics, Inc., Glidewell, Teva Pharmaceutical Industries Ltd, and Axsome Therapeutics, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support